Literature DB >> 10522870

Multisequence MRI in clinically isolated syndromes and the early development of MS.

P A Brex1, J I O'Riordan, K A Miszkiel, I F Moseley, A J Thompson, G T Plant, D H Miller.   

Abstract

OBJECTIVE: To apply multisequence MRI techniques to patients with clinically isolated syndromes, to document the pattern and frequency of abnormalities at baseline and early follow-up, and to determine their predictive values for the early development of clinical MS.
BACKGROUND: Disseminated lesions on T2-weighted brain MRI confer an increased risk of progression to clinically definite MS. Newer MRI techniques increase detection of lesions in both brain and spinal cord, and clarify further their pathology. The predictive value of such techniques for the development of clinical MS needs to be defined.
METHODS: Brain and spinal MRI were performed on 60 patients after their first demyelinating event. A total of 50 patients were followed for 1 year, and 49 underwent repeat brain MRI 3 months after the initial scan.
RESULTS: At baseline, 73% of patients had lesions on T2-weighted fast spin-echo (FSE) brain images and 42% had asymptomatic spinal cord lesions. Fast fluid-attenuated inversion-recovery brain did not improve detection of brain lesions. Repeat brain MRI demonstrated new FSE lesions in 43% of patients. After 1 year, 26% of patients developed MS. The MRI features that provided the best combination of sensitivity and specificity for the development of MS were the presence of new FSE lesions at follow-up and enhancing lesions at baseline. The frequency of developing clinical MS was higher for those with both brain and spinal cord lesions at baseline (48%) than brain lesions alone (18%).
CONCLUSIONS: The combination of baseline MRI abnormalities and new lesions at follow-up, indicating dissemination in space and time, was associated with a high sensitivity and specificity for the early development of clinical MS. These data suggest a potential role for new diagnostic criteria for MS based on early MRI activity. Such criteria may be useful in selecting patients for therapeutic trials at this early clinical stage.

Entities:  

Mesh:

Year:  1999        PMID: 10522870     DOI: 10.1212/wnl.53.6.1184

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

2.  [Differential diagnosis of non-neoplastic space-occupying lesions of the spinal cord].

Authors:  G Schulte-Altedorneburg; F Ahlhelm; A Zimmer; J Viera; A Nabhan; D-A Clevert; A Haass; W Reith
Journal:  Radiologe       Date:  2006-12       Impact factor: 0.635

3.  Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.

Authors:  Petra Nilsson; Elna-Marie Larsson; Pia Maly-Sundgren; Roland Perfekt; Magnhild Sandberg-Wollheim
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

Review 4.  The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis.

Authors:  Rahşan Göçmen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

5.  An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Authors:  Linda Ottoboni; Brendan T Keenan; Pablo Tamayo; Manik Kuchroo; Jill P Mesirov; Guy J Buckle; Samia J Khoury; David A Hafler; Howard L Weiner; Philip L De Jager
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

6.  Comparison of Sagittal FSE T2, STIR, and T1-Weighted Phase-Sensitive Inversion Recovery in the Detection of Spinal Cord Lesions in MS at 3T.

Authors:  P Alcaide-Leon; A Pauranik; L Alshafai; S Rawal; J Oh; W Montanera; G Leung; A Bharatha
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-21       Impact factor: 3.825

7.  Optimized T1-MPRAGE sequence for better visualization of spinal cord multiple sclerosis lesions at 3T.

Authors:  G Nair; M Absinta; D S Reich
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

8.  Horizontal nystagmus and multiple sclerosis using 3-Tesla magnetic resonance imaging.

Authors:  P M Iyer; A J Fagan; J F Meaney; N C Colgan; S D Meredith; D O Driscoll; K M Curran; D Bradley; J Redmond
Journal:  Ir J Med Sci       Date:  2015-12-17       Impact factor: 1.568

9.  Disease-modifying Therapies for Multiple Sclerosis.

Authors:  John R. Corboy; Douglas S. Goodin; Elliot M. Frohman
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

10.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.